Torvutatug samrotecan with bevacizumab as ongoing treatment after first treatment for advanced ovarian cancer
Compares torvutatug samrotecan plus bevacizumab with bevacizumab alone in advanced ovarian cancer.
Plain-language title generated from the registry record
Registry title: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Key facts
- Where
- Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Huangpu District, Jinan, Linyi, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Neijiang, Shanghai, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Weifang, Wenzhou, Wuhan, Xinxiang, and Xuzhou, ChinaSee the 32 sites
- Phase
- Phase 3
Where in China
- AnyangAnyang, ChinaNot yet recruiting
- BeijingBeijing, ChinaNot yet recruiting
- Binzhou ShiBinzhou Shi, ChinaNot yet recruiting
- ChangchunChangchun, ChinaNot yet recruiting
- ChangshaChangsha, ChinaNot yet recruiting
- ChengduChengdu, ChinaNot yet recruiting
- ChongqingChongqing, ChinaNot yet recruiting
- FuzhouFuzhou, ChinaNot yet recruiting
- GuangzhouGuangzhou, ChinaNot yet recruiting
- HaikouHaikou, ChinaNot yet recruiting
- HangzhouHangzhou, ChinaNot yet recruiting
- HefeiHefei, ChinaNot yet recruiting
- Huangpu DistrictHuangpu District, ChinaNot yet recruiting
- JinanJinan, ChinaNot yet recruiting
- LinyiLinyi, ChinaNot yet recruiting
- LuoyangLuoyang, ChinaNot yet recruiting
- LuzhouLuzhou, ChinaNot yet recruiting
- NanchangNanchang, ChinaNot yet recruiting
- NanjingNanjing, ChinaNot yet recruiting
- NanningNanning, ChinaNot yet recruiting
- NeijiangNeijiang, ChinaNot yet recruiting
- ShanghaiShanghai, ChinaNot yet recruiting
- ShantouShantou, ChinaNot yet recruiting
- ShenzhenShenzhen, ChinaNot yet recruiting
- ShijiazhuangShijiazhuang, ChinaNot yet recruiting
- SuzhouSuzhou, ChinaNot yet recruiting
- TaiyuanTaiyuan, ChinaNot yet recruiting
- WeifangWeifang, ChinaNot yet recruiting
- WenzhouWenzhou, ChinaNot yet recruiting
- WuhanWuhan, ChinaNot yet recruiting
- XinxiangXinxiang, ChinaNot yet recruiting
- XuzhouXuzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07851025EU 2026-526895-22-00
- Record updated
- 6 November 2026
- Original description
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.Read full original descriptionShow less
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Non-HRD Positive Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.
Inclusion: Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal carcinoma; Provision of an archival FFPE tumour sample; Participants who have completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation; Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation; Participants who have completed cytoreductive surgery or have inoperable disease; Participants with non-progressive disease upon completion of front-line induction therapy.
Exclusion: Prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC); Participants with history of (non-infectious) ILD/pneumonitis that required steroids or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening; Participants with non-healing wound, active ulcer, or bone fracture; Participants with tumours of non-epithelial origin, borderline tumours, or low-grade epithelial tumours; BRCA1/2 mutation (germline or somatic) or HRD positive, unknown, or inconclusive tumour status; Participants with evidence of active or ongoing bowel obstruction.